NEW YORK, Sept. 8, 2023 /PRNewswire/ -- The Duchenne muscular dystrophy (DMD) therapeutics market size is expected to grow by USD 2.39 billion from 2022 to 2027. In addition, the momentum of the market will progress at a CAGR of 21.2% during the forecast period, according to Technavio Research. The market is segmented by Type (Biologics and Small molecules), Distribution Channel (Offline and Online), and Geography (North America, Europe, Asia, and Rest of World (ROW)). North America will contribute 40% to the growth of the global market during the forecast period. The regional market growth can be attributed to factors such as the dominance of approved therapeutics in the region. EXONDYS 51 from Sarepta, EMFLAZA, and TRANSLNAR by PTC Therapeutics are some of the highly effective drugs in use in the region. Furthermore, owing to the rapidly progressive and fatal nature of Duchenne muscular dystrophy, governments in countries such as the US and Canada have added the indication to the list of diseases that are required to be screened in newborns. Hence, such factors boost the growth of the regional market during the forecast period. This report offers an up-to-date analysis of the current market scenario, the latest trends and drivers, and the overall market environment. Read the PDF Sample Report
Company Profile:
BioMarin Pharmaceutical Inc.. Capricor Therapeutics Inc., CRISPR Therapeutics AG, CVS Health Corp., Daiichi Sankyo Co. Ltd., Editas Medicine Inc., Eli Lilly and Co., F. Hoffmann La Roche Ltd., FibroGen Inc., Italfarmaco Holding SPA, Nippon Shinyaku Co. Ltd., Otsuka Holdings Co. Ltd., Pfizer Inc., PTC Therapeutics Inc., Santhera Pharmaceuticals Holding AG, Sarepta Therapeutics Inc, Solid Biosciences Inc., The Cleveland Clinic Foundation, Vertex Pharmaceuticals Inc., Wave Life Sciences Ltd.
BioMarin Pharmaceutical Inc. - The company offers copper products under the brand Hindalco.
- To gain access to more vendor profiles available with Technavio, buy the report!
Duchenne Muscular Dystrophy (DMD) Therapeutics Market: Segmentation Analysis
By Segment - The biologics segment will be significant during the forecast period. They are substances derived from living organisms and contain certain components of live organisms such as proteins, monoclonal antibodies, peptides, oligonucleotides, genes, or cells. Furthermore, special drug designations from regulatory authorities such as the European Medicines Agency and the US Food and Drug Administration have been obtained for some of the biologics under development. Learn about the contribution of each segment summarized in concise infographics and thorough descriptions. View a PDF Sample Report
"Besides analyzing the current market scenario, our report examines historic data from 2017 to 2021"- Technavio
Duchenne Muscular Dystrophy (DMD) Therapeutics Market: Driver & Trend:
Drivers
- High unmet need among patients with Duchenne muscular dystrophy (DMD)
- Increasing strategic alliances among market vendors
- Availability of patient assistance programs
The high unmet need among patients with Duchenne muscular dystrophy (DMD) drives the growth of the market. Muscular dystrophies affect human skeletal muscles and are clinically and genetically heterogeneous disorders. It is a hereditary childhood myopathy, which leads to progressive muscle weakening and atrophy, and premature death. Also, there has been a significant improvement in the knowledge about disease progress, etiology, and development of effective treatment for Duchenne Muscular Dystrophy. Hence, such factors boost the growth of the DMD market during the forecast period.
Trend
The special drug designation for Duchenne muscular dystrophy (DMD) therapeutics is an emerging DMD market trend.
Identify key trends, drivers, and challenges in the market. Download to gain access to this information.
Related Reports:
The hereditary angioedema (HAE) therapeutics market size is estimated to grow by USD 1,647.38 million at a CAGR of 8.95% between 2022 and 2027. Technavio has segmented the market into End-user, Product, and Geography segments. The growing demand for personalized medicine is a key trend in the hereditary angioedema therapeutics market.
The pulmonary embolism therapeutics market size is estimated to grow at a CAGR of 9.52% between 2022 and 2027. The market size is forecast to increase by USD 10,898.47 million. This pulmonary embolism therapeutics market report extensively covers market segmentation by application (hospitals, ambulatory surgical centers, and research institutes), route of administration (oral and parenteral), and geography (North America, Europe, Asia, and Rest of World (ROW)). The growing risk of adverse health conditions is driving the growth in the pulmonary embolism therapeutic market.
What are the key data covered in this Duchenne muscular dystrophy (DMD) therapeutics market report?
- CAGR of the market during the forecast period
- Detailed information on factors that will drive the growth of the Duchenne muscular dystrophy (DMD) therapeutics market between 2022 and 2027.
- Precise estimation of the Duchenne muscular dystrophy (DMD) therapeutics market size and its contribution to the market in focus on the parent market
- Accurate predictions about upcoming trends and changes in consumer behavior
- Growth of the mental health industry across North America, Europe, Asia, and ROW
- A thorough analysis of the market's competitive landscape and detailed information about vendors
- Comprehensive analysis of factors that will challenge the growth of Duchenne muscular dystrophy (DMD) therapeutics market vendors.
ToC:
Executive Summary
Market Landscape
Market Sizing
Historic Market Sizes
Five Forces Analysis
Market Segmentation by Type
Market Segmentation by Distribution Channel
Market Segmentation by Geography
Customer Landscape
Geographic Landscape
Drivers, Challenges, & Trends
Company Landscape
Company Analysis
Appendix
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com
SOURCE Technavio
Share this article